Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stock Market Movement: Meta Surges on October 13 Due to Muse Retention, Model Release, and Target Price Upgrades

US Stock Market Movement: Meta Surges on October 13 Due to Muse Retention, Model Release, and Target Price Upgrades

Bitget异动解读Bitget异动解读2026/10/13 14:01
Show original

Meta October 13 Surge Analysis

Keywords: Muse retention, model release, target price adjustment

1. On October 13, data disclosed for September showed that Meta's standalone AI assistant Muse had a first-day user retention rate of 73.3% in 81 countries and regions, higher than ChatGPT's 41.3%.

2. On October 12, Meta released Muse Wonder and Muse Wonder Full, stating they are the company's most powerful AI models to date; Muse Wonder will be used for the personal AI assistant Muse and will be prioritized for subscription users.

3. On October 13, Truist raised Meta's target price from $763 to $1,000, and Pivotal Research raised the target price from $790 to $930, both maintaining a Buy rating; both institutions mentioned Muse's early adoption.

(Disclaimer: This content is summarized and generated by AI technology based on publicly available information and is for reference only, not constituting investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%